PolyPid's D-PLEX₁₀₀ Clears EMA Hurdle, Awaits FDA Decision

Event summary

EMA validates PolyPid's MAA for D-PLEX₁₀₀, initiating formal review under Centralized Procedure.
D-PLEX₁₀₀'s NDA under FDA Priority Review with PDUFA goal date of November 28, 2026.
Phase 3 SHIELD II trial showed 60% relative risk reduction in surgical site infections.
PolyPid retains commercial rights to D-PLEX₁₀₀ outside U.S. and Canada, partnered with Azurity Pharmaceuticals.

The big picture

PolyPid's dual-regulatory progress positions D-PLEX₁₀₀ for potential simultaneous approval in the U.S. and EU, addressing a critical unmet need in surgical site infection prevention. The company's strategic focus on localized drug delivery aligns with broader industry trends toward precision medicine and combating antibiotic resistance. Success here could validate PolyPid's platform technology for other applications in its pipeline.

What we're watching

Regulatory Timing: Whether EMA's review process will align with FDA's November 28, 2026 PDUFA goal date for D-PLEX₁₀₀.
Market Potential: How PolyPid will leverage D-PLEX₁₀₀'s approval to capture share in the significant European SSI market.
Commercial Strategy: The pace at which PolyPid advances its diverse pipeline while preparing for D-PLEX₁₀₀'s potential dual-market launch.